Bone Biologics (NASDAQ:BBLG – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.02, FiscalAI reports.
Bone Biologics Trading Down 2.4%
Shares of Bone Biologics stock opened at $0.37 on Wednesday. Bone Biologics has a 52-week low of $0.36 and a 52-week high of $2.39. The company’s 50-day simple moving average is $0.51 and its 200-day simple moving average is $1.08.
Analysts Set New Price Targets
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bone Biologics in a research note on Thursday, October 22nd. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.
Read Our Latest Research Report on BBLG
About Bone Biologics
Bone Biologics Corporation (NASDAQ: BBLG) is a biotechnology company focused on developing regenerative medicine products for the orthopedic and spine markets. Its work centers on bone growth and spinal fusion, where physicians use biologic materials and implants to help stabilize the spine and support the formation of new bone.
The company’s primary technology is based on NELL-1, a recombinant human protein that has demonstrated bone-forming properties in preclinical and clinical research.
Read More
- Five stocks we like better than Bone Biologics
- Is United Parcel Service Finally Turning the Corner?
- Taiwan Semiconductor Flexes Pricing Power on AI’s Frontline
- Hidden in Plain Sight: 2 Earnings Winners Investors May Have Missed
- These 3 New ETFs Are Turning Heads—Are They Worth Buying?
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
